Passive Immune-oncology Therapy (New Antibody Drug)
A passive immuno-oncology therapy based on a monoclonal antibody that targets Globo H, OBI-888 completed a single-dose toxicity study in primates with no major adverse reactions observed. It is currently undergoing repeated-dose toxicity studies. The sequence of OBI-888 was filed for international patent applications (PCT) and is currently under review (National Phase). An IND application is expected in the fourth quarter of 2017.